
FDA Approved Bysanti: a New Antipsychotic for Schizophrenia and Bipolar I
The February 20, 2026 approval of milsaperidone adds a fresh side-effect profile to a class dominated by generics. What it means for patients and payers.
Sector news category — verified health events only (FDA, guidelines, major studies)

The February 20, 2026 approval of milsaperidone adds a fresh side-effect profile to a class dominated by generics. What it means for patients and payers.

A January 5, 2026 announcement tied to a presidential memorandum set off schedule changes, court challenges, and a postponed ACIP meeting. What parents should know.

The January 12, 2026 approval of copper histidinate gives infants with the rare ATP7A disorder a standardized, FDA-reviewed treatment option.